Novartis plans to answer a U.S. senator who demanded details about data manipula...
FILE PHOTO: Swiss drugmaker Novartis' logo is seen at the company's plant in the northern Swiss town of Stein, Switzerland October 23, 2017. REUTERS/Arnd Wiegmann/File Photo
ZURICH - Novartis plans to answer a U.S. senator who demanded details about data manipulation related to its gene therapy Zolgensma, amid scrutiny of the Swiss drugmaker’s decision to delay informing regulators until after the treatment’s approval.U.S. Senate Finance Committee Chairman Chuck Grassley has asked the Basel-based company to give details on data manipulation on its $2.1 million gene therapy to treat spinal muscular atrophy by Aug. 23.
Novartis, which won approval for Zolgensma in May — more than a month before it told the Food and Drug Administration of the alleged data fraud — has terminated several scientists amid an internal investigation.
México Últimas Noticias, México Titulares
Similar News:También puedes leer noticias similares a ésta que hemos recopilado de otras fuentes de noticias.
Gun safety advocates hold rallies across the nation calling for Senate actionGun safety advocacy groups are holding rallies in cities across the United States urging the Senate to end their recess early and act on gun reform legislation. NBC's Simone Boyce reports from the Los Angeles rally.
Leer más »
Novartis executive sold shares before drug data manipulation made publicAn unnamed Novartis executive sold 925,400 Swiss francs ($946,000) worth of shar...
Leer más »
Novartis CEO Battles Fallout From Data ManipulationNovartis Chief Executive Vas Narasimhan has spent part of his 18 months at the helm of the drug giant cleaning up issues that emerged before his watch. Now, he is facing a storm of his own making.
Leer más »
Do Natural Sleep Aids Like Melatonin and Valerian Actually Work?Here’s what two doctors and a holistic nutritionist recommend, and, crucially, how they recommend it
Leer más »